Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
coronavac
- Development stage
- Phase 4
- Lead developer
- Sinovac Biotech
- Modality
- Whole Inactivated Vaccines → Inactivated Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
CoronaVac is a whole inactivated virus COVID-19 vaccine developed by Sinovac Biotech for the prevention of COVID-19. It contains chemically inactivated SARS-CoV-2 virus particles and is adjuvanted with aluminum hydroxide to enhance immune response. The vaccine works by exposing the immune system to the entire killed virus, stimulating both humoral (antibody-mediated) and cell-mediated immunity against multiple viral proteins, including spike and nucleocapsid proteins. Clinical trials have shown that two doses provide moderate efficacy against symptomatic infection but high protection against severe disease and hospitalization. CoronaVac has been approved for use in many countries worldwide for adults aged 18 years and older[1][2][3][8].
- Brand names
- coronavac
- Other names
- sinovac covid-19 vaccinecovid-19 vaccine (vero cell) inactivatedsinovac-coronavac covid-19 vaccine
02
Targets
SARS-CoV-2 spikeN (Nucleocapsid protein)
Beyond the preview
Go deeper on coronavac.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on coronavac.